|
 |
 |
|
 |
 |
|
FRIDAY,
DECEMBER 7, 2007
Great Debates in CLL: Facing Today's Controversies and Tomorrow's Challenges
A luncheon satellite symposium preceding the 49th Annual Meeting of the American Society of Hematology
Chair:
Susan
O'Brien, MD
MD Anderson Cancer
Center
Houston, Texas
Click
here to register
for this complimentary
educational program.
|
 |
|
F A C
U L T
Y |
 |
|
|
John
Byrd,
MD
The
Ohio
State
University
College
of
Medicine
&
Public
Health
Columbus,
Ohio
Martin
Dyer,
MD
Leicester
Royal
Infirmary
Leicester,
United
Kingdom
|
Alessandra
Ferrajoli,
MD
MD
Anderson
Cancer
Center
Houston,
Texas
Susan
O'Brien,
MD
MD
Anderson
Cancer
Center
Houston,
Texas
|
Stephan
Stilgenbauer,
MD
University
of
Ulm
Ulm,
Germany
Mark
A.
Weiss,
MD
Memorial
Sloan-Kettering
Cancer
Center
New
York,
New
York
|
|
|
|
S C I
E N T
I F I
C
P R O
G R A
M |
|
|
|
12:30
pm
Lunch
1:00
pm
Introductions
Susan
O’Brien,
MD
1:05
pm
The
Clinical
Challenges
in
CLL
Today
Susan
O’Brien,
MD
1:15
pm
Debate:
What
should
be
the
Standard
of
Care
for
First
Line
Therapy
of
CLL?
Fludarabine-Based
Combinations
Susan
O’Brien,
MD
Non-Fludarabine
Based
Therapies
Martin
Dyer,
MD
Q
&
A
1:50
pm
Debate:
Should
Biologic
&
Molecular
Prognostic
Markers
be
used
to
Assign
and
Guide
Therapy
for
CLL
Patients?
Yes
Stephan
Stilgenbauer,
MD
No
Mark
A.
Weiss,
MD
Q
&
A
2:25
pm
Debate:
Is
it
Necessary
to
Treat
to
MRD
Negativity
to
Achieve
Maximal
Clinical
Benefit
in
CLL?
Yes
Martin
Dyer,
MD
No
Alessandra
Ferrajoli,
MD
Q
&
A
3:00
pm
Emerging
Novel
Therapies
for
CLL
John
Byrd,
MD
3:30
pm
CLL:
A
Vision
for
the
Future
Cases
and
Panel
Discussion
Moderator:
Susan
O’Brien,
MD
4:30
pm
Adjourn
|
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex,
LLC
designates
this
educational
activity
for
a
maximum
3.50
of
AMA
PRA
Category
1
Credit(s)™.
Physicians
should
only
claim
credit
commensurate
with
the
extent
of
their
participation
in
the
activity.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
specifically
designed
for
hematologists,
internists,
oncologists
and
other
physicians,
physicians-in-training,
and
healthcare
professionals
(nurses,
pharmacists)
interested
in
and/or
involved
in
the
care
of
patients
with
chronic
lymphocytic
leukemia
(CLL).
No
specialized
knowledge
or
skill
other
than
general
familiarity
with
hematology
or
internal
medicine
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
Upon
completion
of
this
educational
activity,
attendees
should
be
able
to:
- State
the
rationale
for
treating
or
not
treating
patients
with
CLL
-
Describe
and
discuss
the
value
of
molecular
and
biologic
markers
in
determining
prognosis
and
planning
treatment
for
CLL
patients
-
Compare
and
contrast
the
various
therapeutic
regimens
used
as
first-line
treatments
of
CLL
-
Explain
the
different
treatment
options
for
managing
minimal
residual
CLL
disease
-
Design
appropriate
therapeutic
plan(s)
for
the
effective
management
of
relapsed
and
refractory
disease
in
CLL
-
Discuss
the
recent
clinical
trials
looking
at
new
treatment
modalities
for
CLL
and
explain
how
these
modalities
will
be
applied
in
the
future
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here
to
register
for
this
program
This
is
a
complimentary
educational
program
and
space
is
limited.
To
confirm
your
attendance,
please
register
by
December
3,
2007.
To
ensure
admittance,
please
bring
your
registration
confirmation
to
the
symposium.
To
register,
you
may
register
online
or
call
Imedex
at
+1
(678)
242
0906.
If
you
mail
the
form,
please
keep
a
copy
for
your
records.
Registration
confirmations
will
be
issued
before
the
meeting.
Please
bring
your
registration
confirmation
to
the
symposium
to
ensure
entry.
|
|
|
|
G
E N E
R A L
I N F
O R M
A T I
O N |
|
|
|
Date:
Friday,
December
7,
2007
Time:
12:30
pm
–
4:30
pm
Location:
The
Georgia
World
Congress
Center
Sidney
Marcus
Auditorium
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex®,
LLC. All rights
reserved.
|
|
